Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The study is to investigate the safety, tolerability, and pharmacokinetics (the determination
of the concentration of the administered drug in blood over time) of recombinant Factor VIII
Fc fusion protein (rFVIIIFc) in previously-treated subjects with severe hemophilia A.